Breaking News

Catalent in Commercial Supply Pact with Palatin

Will produce bremelanotide pen injector at Brussels sterile fill finish facility

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent Pharma Solutions has entered a commercial supply agreement to support the global commercial product launch of Palatin Technologies’ bremelanotide pen injector product for the treatment of female sexual dysfunction (FSD).   Bremelanotide, a subcutaneous injectable peptide melanocortin receptor agonist, is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women. Phase III clinical trials are underway, with a commercial launch anticipated ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters